Clinical trial
Treatment of Peripheral Neuropathy in Patients With Diabetes
NCT00044421 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00044421 |
|---|---|
| Title | Treatment of Peripheral Neuropathy in Patients With Diabetes |
| Official title | LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Neuropathies, Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Ruboxistaurin mesylate |
| Enrollment | 400 |
| Start date | Jul 1, 2002 |
| Completion | Oct 1, 2006 |
| First posted | Aug 30, 2002 |
| Last update posted | Nov 6, 2007 |
| Countries | Australia, Belgium, Canada, Croatia, Denmark, Estonia, Finland, Germany, Hungary, India, Lithuania, Netherlands and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: